{
    "clinical_study": {
        "@rank": "163188", 
        "acronym": "PENTA 13", 
        "arm_group": [
            {
                "arm_group_label": "Twice daily", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Once daily", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Cross-over 28 week study of the plasma pharmacokinetic profiles of twice daily 3TC\n      (4mg/kg/dose BD) with once daily 3TC (8mg/kg/dose OD) and twice daily ABC (8mg/kg/dose BD)\n      with daily ABC (16mg/kg/dose OD) where one or both drugs are being taken as part of\n      combination antiretroviral therapy."
        }, 
        "brief_title": "Pharmacokinetic (PK) Study of Twice Daily vs Once Daily Lamivudine (3TC) and Abacavir (ABC) as Part of Combination Antiretroviral Therapy (ART) in HIV Infected Children", 
        "completion_date": {
            "#text": "March 2004", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infection", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children with definitive HIV infection\n\n          -  Age > 2 and < 13 years\n\n          -  Currently on combination ART including 3TC and / or ABC, for at least 6 months, with\n             stable CD4 cell count and HIV RNA viral load and expected to stay on this regimen for\n             at least a further 3 months.\n\n        Exclusion Criteria:\n\n          -  \u2022 Intercurrent illness\n\n               -  Receiving concomitant therapy except prophylaxis against Pneumocystis carinii\n                  pneumonia (PCP)\n\n               -  Abnormal renal or liver function (grade 3 or above)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "13 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "19", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01982396", 
            "org_study_id": "PENTA 13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Twice daily", 
                "intervention_name": "ABC Twice Daily", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Once daily", 
                "intervention_name": "ABC Once Daily", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Once daily", 
                "intervention_name": "3TC Once Daily", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Twice daily", 
                "intervention_name": "3TC Twice Daily", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Lamivudine", 
                "Abacavir"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV", 
            "paediatric", 
            "Abacavir", 
            "lamivudine"
        ], 
        "lastchanged_date": "November 5, 2013", 
        "link": {
            "description": "PENTA 13 publications and presentations", 
            "url": "http://www.penta-id.org/hiv/penta-trials/penta-trials-publications/49-penta-13.html"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Great Ormond Street Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "St. Mary's Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacokinetic Study of Twice Daily vs Once Daily Lamivudine and Abacavir as Part of Combination Antiretroviral Therapy in Children With HIV Infection", 
        "other_outcome": {
            "measure": "To describe patient and family acceptability of and adherence to once daily compared to twice daily dosing", 
            "safety_issue": "No", 
            "time_frame": "week -2 and week 24"
        }, 
        "overall_official": [
            {
                "affiliation": "Great Ormond Street Hospital for Children, London, UK", 
                "last_name": "Vas Novelli, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "St. Mary's Hospital,  London, UK", 
                "last_name": "Hermione Lyall, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Department of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area Under Curve (AUC) of lamivudine after qd and bid dosing", 
                "safety_issue": "No", 
                "time_frame": "week 0 and Week 4"
            }, 
            {
                "measure": "Cmin of lamivudine after qd and bid dosing", 
                "safety_issue": "No", 
                "time_frame": "week 0 and week 4"
            }, 
            {
                "measure": "Cmax of lamivudine after qd and bid dosing", 
                "safety_issue": "No", 
                "time_frame": "week 0 and week 4"
            }, 
            {
                "measure": "AUC of abacavir after qd and bid dosing", 
                "safety_issue": "No", 
                "time_frame": "week 0 and week 4"
            }, 
            {
                "measure": "Cmin of abacavir after qd and bid dosing", 
                "safety_issue": "No", 
                "time_frame": "week 0 and week 4"
            }, 
            {
                "measure": "Cmax of abacavir after qd and bid dosing", 
                "safety_issue": "No", 
                "time_frame": "week 0 and week 4"
            }
        ], 
        "reference": [
            {
                "PMID": "15865218", 
                "citation": "Bergshoeff A, Burger D, Verweij C, Farrelly L, Flynn J, Le Prevost M, Walker S, Novelli V, Lyall H, Khoo S, Gibb D; PENTA-13 Study Group. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther. 2005;10(2):239-46."
            }, 
            {
                "PMID": "16732152", 
                "citation": "LePrevost M, Green H, Flynn J, Head S, Clapson M, Lyall H, Novelli V, Farrelly L, Walker AS, Burger DM, Gibb DM; Pediatric European Network for the Treatment of AIDS 13 Study Group. Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children. Pediatr Infect Dis J. 2006 Jun;25(6):533-7."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01982396"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To describe trough intracellular levels of 3TC on twice daily and once daily dosage regimens", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and week 4"
            }, 
            {
                "measure": "To describe trough intracellular levels of 3TC on twice daily and once daily dosage regimens", 
                "safety_issue": "No", 
                "time_frame": "week 0 and week 4"
            }
        ], 
        "source": "PENTA Foundation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PENTA Foundation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2003", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}